Transcode Therapeutics
Newton
About Transcode Therapeutics
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, which they believe has blockbuster potential, targets an RNA molecule that is the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in its lab at MGH.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $73.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Oct 2025)
- Ticker: nasdaq:RNAZ
- Website: transcodetherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/transcode-therapeutics-39306 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.